Skip to main content

Kaitai Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

80
Companies
$874.5M
Total invested
$16.5M
Avg. check
32
Industries
Biotechnology 14Pharmaceutical 9Medical 6Health Care 6Biopharma 5Software 5+26 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 80
TechnoDerma Medicines
January 2024

TechnoDerma Medicines is engaged in the research and development of skin drugs for external use.

Biotechnology · XuzhouSeries A
Phanes Therapeutics
January 2024

Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for solid tumors and eye diseases

Biotechnology · San DiegoSeries Unknown
Ceram Pharmaceuticals
December 2023

Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases.

Biotechnology · Shenzhen$14.0M Series A
Atom Bioscience & Pharmaceutical
October 2023

Atom Bioscience is a clinical-stage biotechnology company.

Biotechnology · Suzhou$82.1M Series D
Nafi Pharmaceuticals
September 2023

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Biotechnology · ShenzhenSeries A
Astrocyte Pharmaceuticals
August 2023

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.

Biotechnology · Cambridge$6.0M Series B
CirCode
August 2023

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Biotechnology · ShanghaiSeries A
Circular Code Biology
August 2023

Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

Biopharma · ShanghaiSeries A
Hongyun Biotech
May 2023

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Biotechnology · Nanjing$14.4M Series B
Databaker
April 2023

Databaker is an AI data service company that provides speech synthesis, speech recognition, and image recognition data services.

Artificial Intelligence (AI) · Beijing$14.6M Series B
Primelink Bio
November 2022

Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.

Biopharma · Tongyuan$13.9M Series Unknown
Lupeng Pharmaceutical
November 2022

Lupeng Pharmaceutical is a biotech company that focuses on the drug discovery and development of novel therapies for cancer treatment.

Biotechnology · Guangzhou$35.0M Series A
Realibox
September 2022

Realibox delivers digital designing and cloud platform solutions for enterprises.

3D Technology · Guangzhou$14.0M Series A
Aoquan
August 2022

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

Biopharma · Shanghai$14.8M Series B
Wangfanxin
July 2022

Wangfanxin is a supplier of business process management software products that support data processing and lean enterprise management.

Big Data · Shanghai$14.8M Series A
Apache DolphinScheduler
July 2022

Apache DolphinScheduler is a distributed and extensible workflow scheduler platform with powerful DAG visual interfaces.

Cloud Computing · Beijing$10.0M Angel
Yiwise
June 2022

Yiwise is a research and development artificial intelligence company.

Artificial Intelligence (AI) · HangzhouSeries B
Worktile
April 2022

Worktile is a Enterprise services Startup Based in Beijing.

Enterprise · Beijing$15.2M Series C
Ke Ning Bio
April 2022

Ke Ning Bio is an ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs.

Biotechnology · Shenzhen$15.7M Seed
TaoCloud
February 2022

TaoCloud is a software-defined storage solution provider.

Enterprise · Haidian$866K Series C
Bichen Pharmaceutical
January 2022

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Biopharma · Shanghai$30.0M Series B
TianTi Biotherapeutics
December 2021

TianTi Biotherapeutics is a biotechnology company that provides research and development of antibody drugs.

Biopharma · Woburn$15.6M Series A
BioBin Data Science
December 2021

BioBin Data Science is a technology firm specializing in custom software development, big data, and intelligent breeding data platforms.

Agriculture · Changsha$1.6M Seed
Mingsight Pharmaceuticals
November 2021

Mingsight Pharmaceuticals is a pharmaceutical company engaged in developing ophthalmic medical drugs.

Biotechnology · San Diego$20.0M Series B

Where Kaitai Capital invests

Biotechnology14
Pharmaceutical9
Medical6
Health Care6
Biopharma5
Software5

About Kaitai Capital's portfolio

How many companies has Kaitai Capital invested in?

Kaitai Capital has invested in 80 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Kaitai Capital invest in?

Kaitai Capital's top investment sectors include Biotechnology, Pharmaceutical, Medical, Health Care, Biopharma. The firm invests across 32 different industry categories.

What is Kaitai Capital's largest investment?

Among tracked funding rounds, Atom Bioscience & Pharmaceutical received $82.1M in a Series D round. Kaitai Capital's total known invested capital is $874.5M.

What is the average investment size for Kaitai Capital?

Kaitai Capital's average investment size is $16.5M across its portfolio of 80 companies.

What are Kaitai Capital's most recent investments?

Recent Kaitai Capital portfolio additions include TechnoDerma Medicines, Phanes Therapeutics, Ceram Pharmaceuticals, Atom Bioscience & Pharmaceutical, Nafi Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 80 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →